The main steps in the development of anticancer agents

G. Schwartsmann, B. Winograd, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.

Original languageEnglish (US)
Pages (from-to)301-313
Number of pages13
JournalRadiotherapy and Oncology
Volume12
Issue number4
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Phase IV Clinical Trials
Phase III Clinical Trials
Cytotoxins
Antineoplastic Agents
Toxicology
Pharmaceutical Preparations
Clinical Studies

Keywords

  • Anticancer agents
  • Clinical trials
  • Drug development

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

The main steps in the development of anticancer agents. / Schwartsmann, G.; Winograd, B.; Pinedo, H. M.

In: Radiotherapy and Oncology, Vol. 12, No. 4, 1988, p. 301-313.

Research output: Contribution to journalArticle

Schwartsmann, G, Winograd, B & Pinedo, HM 1988, 'The main steps in the development of anticancer agents', Radiotherapy and Oncology, vol. 12, no. 4, pp. 301-313. https://doi.org/10.1016/0167-8140(88)90020-5
Schwartsmann, G. ; Winograd, B. ; Pinedo, H. M. / The main steps in the development of anticancer agents. In: Radiotherapy and Oncology. 1988 ; Vol. 12, No. 4. pp. 301-313.
@article{09557a00687c4d6fb23efa36b3c77bcc,
title = "The main steps in the development of anticancer agents",
abstract = "The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.",
keywords = "Anticancer agents, Clinical trials, Drug development",
author = "G. Schwartsmann and B. Winograd and Pinedo, {H. M.}",
year = "1988",
doi = "10.1016/0167-8140(88)90020-5",
language = "English (US)",
volume = "12",
pages = "301--313",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - The main steps in the development of anticancer agents

AU - Schwartsmann, G.

AU - Winograd, B.

AU - Pinedo, H. M.

PY - 1988

Y1 - 1988

N2 - The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.

AB - The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.

KW - Anticancer agents

KW - Clinical trials

KW - Drug development

UR - http://www.scopus.com/inward/record.url?scp=0023675958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023675958&partnerID=8YFLogxK

U2 - 10.1016/0167-8140(88)90020-5

DO - 10.1016/0167-8140(88)90020-5

M3 - Article

C2 - 3055073

AN - SCOPUS:0023675958

VL - 12

SP - 301

EP - 313

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 4

ER -